Vvax001 / ViciniVax - LARVOL DELTA

Latest generation therapies for the management of HPV infections (FIGO 2025) - "Vvax001 (University Medical Centre Groningen): In a Phase II trial, this therapeutic vaccine targeting HPV type 16 induced regression in high-grade precancerous cervical lesions (CIN3), presenting a potential alternative to standard surgical treatments...INO-3112 (Inovio Pharmaceuticals): A DNA vaccine combining HPV16/18 E6 and E7 antigens with IL-12, studied in combination with durvalumab for recurrent or metastatic HPV-positive head and neck squamous cell carcinoma (HNSCC)...Immunotherapies: Immunotherapy approaches are being explored to treat HPV-related cancers: - Combination therapies. - Oncolytic viruses: Transgene's TG4001 is a therapeutic vaccine expressing HPV-16 E6/E7 antigens, currently under evaluation for recurrent or metastatic HPV16-positive cancers."

IO biomarker • Cervical Cancer • Head and Neck Cancer • Human Papillomavirus Infection • Infectious Disease • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • IL12A

Vvax001, a Therapeutic Vaccine for Patients with HPV16-positive High-grade Cervical Intraepithelial Neoplasia: a Phase II Trial. (PubMed, Clin Cancer Res) - "Treatment with Vvax001 is safe, feasible, and shows preliminary clinical effectiveness in patients with HPV16-associated CIN3 lesions."

Journal • P2 data • Cervical Cancer • Gynecology • Human Papillomavirus Infection • Infectious Disease • Oncology

Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II (clinicaltrials.gov) - P2 | N=18 | Recruiting | Sponsor: University Medical Center Groningen

New P2 trial • Cervical Cancer • Gynecology • Infectious Disease • Oncology